Healthcare Industry News: NeoCart
News Release - June 10, 2013
Histogenics Announces Peter Greenleaf as CEOFormer MedImmune President Brings Extensive Development and Commercial Experience to Late-Stage Regenerative Medicine Company
WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Histogenics Corp., a regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products primarily for orthopedic tissue repair, today announced the appointment of Peter Greenleaf to Chief Executive Officer.
“Peter’s expertise in growing smaller biotech companies into industry leaders will be critical as we work to move NeoCart through pivotal trials and ultimately toward launch and commercialization,” said Histogenics Chairman and Sofinnova Ventures General Partner, Garheng Kong. “While NeoCart will be the main focus in the near term, Peter will also help facilitate our vision for building out the company’s platform technology and the future growth plans for the organization.”
“The team at Histogenics has done an outstanding job to date, and I am happy to be joining them,” said Peter Greenleaf, Chief Executive Officer of Histogenics. “NeoCart is an exciting solution for patients because it creates a personalized hyaline-like cartilage tissue implant for patients using their own cells, which may potentially result in a durable, long-lasting patient response. In the world of knee cartilage injuries, the longevity of patient response is critical because people want to be able to get active again—and stay active.”
Prior to MedImmune, Mr. Greenleaf held several key leadership roles at Centocor, most recently as the Vice President of the U.S. gastroenterology commercial group. Before Centocor, he held roles at Hallmark Cards, Inc., Boehringer Mannheim and U.S. Healthcare. Mr. Greenleaf is a previous board and executive committee member of the Biotechnology Industry Organization (BIO) and the University of Maryland Baltimore Foundation, Inc., and he currently chairs the Maryland Venture Fund Authority. His previous board appointments include Rib-X Pharmaceuticals, LigoCyte Pharmaceuticals and Corridor Pharmaceuticals. He received a Master of Business Administration from St. Joseph’s University and a Bachelor of Science from Western Connecticut State University.
Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. Histogenics’ key product initiatives are focused on providing treatment options for active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering NeoCartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials in which the NeoCart® autologous tissue implant was compared to that of standard microfracture surgery.
Histogenics is conducting a Phase 3 clinical trial to evaluate the safety and efficacy of the NeoCart® cartilage tissue implant when compared to microfracture surgery. Based in Waltham, Massachusetts, the company is privately held. For more information, visit www.histogenics.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.